Tag: Press Release

Oncotarget News

Suppression of Cancer Stemness and Drug Resistance via BRAF/EGFR/MEK Inhibition in Colorectal Cancer Cells

Suppression of Cancer Stemness and Drug Resistance via BRAF/EGFR/MEK Inhibition in Colorectal Cancer Cells

October 11, 2023

our approach enables mechanistic studies of drug resistance with 3D cultures of primary cancer cells to develop and test treatments that suppress cancer [...].”BUFFALO, NY- October 11, 2023 – A new... read more

Figure 1: (A) Canonical STAT3 activation pathway. (B) WP1066 and TTI-101, examples of small molecule STAT3 inhibitors that are cell penetrant.

STAT3 as a Target in H3K27M-mutant DMGs

October 9, 2023

Children diagnosed with these tumors have [...] a median survival of approximately 12 months.” BUFFALO, NY- October 9, 2023 – A new editorial perspective was published in Oncotarget's Volume 14 on... read more

Figure 2: UGDH’s roles in cancer biology.

UGDH in Clinical Oncology and Cancer Biology

October 4, 2023

Given the potential challenges of directly inhibiting UGDH, therapeutic strategies may extend to targeting downstream pathways and upstream substrates.” BUFFALO, NY- October 4, 2023 – A new review paper was... read more

ancient anti-cancer mechanism

An Ancient Anti-cancer Mechanism: DISE

October 3, 2023

DISE is effective against all cancers we tested.” BUFFALO, NY- October 3, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on September 25, 2023, entitled, “DISE,... read more

Oncotarget

<img width="300" height="100" data-src="https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-300x100.png" class="alignleft blogfeed wp-post-image lazyload" alt="Oncotarget" decoding="async" loading="lazy" data-srcset="https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-300x100.png 300w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-1024x341.png 1024w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-768x256.png 768w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-1200x400.png 1200w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1.png 1500w" data-sizes="(max-width: 300px) 100vw, 300px" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" style="--smush-placeholder-width: 300px; --smush-placeholder-aspect-ratio: 300/100;" /><noscript><img width="300" height="100" data-src="https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-300x100.png" class="alignleft blogfeed wp-post-image lazyload" alt="Oncotarget" decoding="async" loading="lazy" data-srcset="https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-300x100.png 300w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-1024x341.png 1024w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-768x256.png 768w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-1200x400.png 1200w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1.png 1500w" data-sizes="(max-width: 300px) 100vw, 300px" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" style="--smush-placeholder-width: 300px; --smush-placeholder-aspect-ratio: 300/100;" /><noscript><img width="300" height="100" src="https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-300x100.png" class="alignleft blogfeed wp-post-image" alt="Oncotarget" decoding="async" loading="lazy" srcset="https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-300x100.png 300w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-1024x341.png 1024w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-768x256.png 768w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-1200x400.png 1200w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1.png 1500w" sizes="(max-width: 300px) 100vw, 300px" />

Reassessing COVID-19 Precautions in 2023

September 27, 2023

The balance between appropriate precautions and the harm of social isolation always requires a thorough appraisal.”BUFFALO, NY- September 27, 2023 – A new editorial paper was published in Oncotarget's Volume... read more